title: Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology.
authors.forename: J L
authors.initials: JL
authors.lastname: Fleiss
authors.forename: J T
authors.initials: JT
authors.lastname: Bigger
authors.forename: M
authors.initials: M
authors.lastname: McDermott
authors.forename: J P
authors.initials: JP
authors.lastname: Miller
authors.forename: T
authors.initials: T
authors.lastname: Moon
authors.forename: A J
authors.initials: AJ
authors.lastname: Moss
authors.forename: D
authors.initials: D
authors.lastname: Oakes
authors.forename: L M
authors.initials: LM
authors.lastname: Rolnitzky
authors.forename: T M
authors.initials: TM
authors.lastname: Therneau
mesh_terms: D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D009203:Myocardial Infarction; D012107:Research Design